ArticlePharmacological reports : PR2021

M-134, a novel HDAC6-selective inhibitor, markedly improved arthritic severity in a rodent model of rheumatoid arthritis when combined with tofacitinib.

Daekwon Bae et al.PubMed ↗Publisher ↗

No numbers read from the abstract.